Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wayne Childers

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry|August 18, 2015
Heterocyclic chalcone activators of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) with improved in vivo efficacyNicole Lounsbury, George Mateo, Brielle Jones, et al.
Journal of Chemical Information and Modeling|August 17, 2021
Discovery of Novel Small-Molecule Inhibitors of SARS-CoV-2 Main Protease as Potential Leads for COVID-19 TreatmentAnjela Manandhar, Vunnam Srinivasulu, Mohamad Hamad, et al.
Bioorganic & Medicinal Chemistry|January 30, 2008
Disruption of Kv1.1 N-type inactivation by novel small molecule inhibitors (disinactivators)Qiang Lu, Joseph Peevey, Flora Jow, et al.
Leukemia & Lymphoma|October 3, 2018
Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemiaMargaret Nieborowska-Skorska, Silvia Maifrede, Min Ye, et al.
Bioorganic & Medicinal Chemistry Letters|November 26, 2009
Synthesis and structure-activity relationship of novel lactam-fused chroman derivatives having dual affinity at the 5-HT(1A) receptor and the serotonin transporterZhongqi Shen, P Siva Ramamoorthy, Nicole T Hatzenbuhler, et al.
Research Square|April 17, 2023
Haploinsufficiency of ZNF251 causes DNA-PKcs-dependent resistance to PARP inhibitors in BRCA1-mutated cancer cellsHuan Li, Srinivas Chatla, Xiaolei Liu, et al.
Bioorganic & Medicinal Chemistry|January 11, 2014
Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradicationSurendrachary Munagala, Gopal Sirasani, Praveen Kokkonda, et al.
Bioorganic & Medicinal Chemistry Letters|June 3, 2017
Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3Kα/mTOR inhibitorsAisha A K Al-Ashmawy, Fatma A Ragab, Khaled M Elokely, et al.
Cancer Letters|February 1, 2025
ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombinationHuan Li, Srinivas Chatla, Xiaolei Liu, et al.
Blood|July 10, 2013
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profileKimberly Cramer-Morales, Margaret Nieborowska-Skorska, Kara Scheibner, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry|August 18, 2015
Heterocyclic chalcone activators of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) with improved in vivo efficacyNicole Lounsbury, George Mateo, Brielle Jones, et al.
Journal of Chemical Information and Modeling|August 17, 2021
Discovery of Novel Small-Molecule Inhibitors of SARS-CoV-2 Main Protease as Potential Leads for COVID-19 TreatmentAnjela Manandhar, Vunnam Srinivasulu, Mohamad Hamad, et al.
Bioorganic & Medicinal Chemistry|January 30, 2008
Disruption of Kv1.1 N-type inactivation by novel small molecule inhibitors (disinactivators)Qiang Lu, Joseph Peevey, Flora Jow, et al.
Leukemia & Lymphoma|October 3, 2018
Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemiaMargaret Nieborowska-Skorska, Silvia Maifrede, Min Ye, et al.
Bioorganic & Medicinal Chemistry Letters|November 26, 2009
Synthesis and structure-activity relationship of novel lactam-fused chroman derivatives having dual affinity at the 5-HT(1A) receptor and the serotonin transporterZhongqi Shen, P Siva Ramamoorthy, Nicole T Hatzenbuhler, et al.
Research Square|April 17, 2023
Haploinsufficiency of ZNF251 causes DNA-PKcs-dependent resistance to PARP inhibitors in BRCA1-mutated cancer cellsHuan Li, Srinivas Chatla, Xiaolei Liu, et al.
Bioorganic & Medicinal Chemistry|January 11, 2014
Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradicationSurendrachary Munagala, Gopal Sirasani, Praveen Kokkonda, et al.
Bioorganic & Medicinal Chemistry Letters|June 3, 2017
Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3Kα/mTOR inhibitorsAisha A K Al-Ashmawy, Fatma A Ragab, Khaled M Elokely, et al.
Cancer Letters|February 1, 2025
ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombinationHuan Li, Srinivas Chatla, Xiaolei Liu, et al.
Blood|July 10, 2013
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profileKimberly Cramer-Morales, Margaret Nieborowska-Skorska, Kara Scheibner, et al.
Pageof 4